Drugs / SPY002-072
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06622070 | Nov 2024 → Apr 2026 overdue | — | Spyre Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07148414 | Aug 2025 → Oct 2026 expected | psoriatic arthritis, spondyloarthropathy | Spyre Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPY002-072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622070 ↗ |